(4H-thieno[3,2-c]chromen4-yl)methanamine | 1310427-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: (4H-thieno[3,2-c]chromen4-yl)methanamine
• 英文别名: 4H-thieno[3,2-c]chromen-4-ylmethanamine
• CAS: 1310427-21-4
• 化学式: C₁₂H₁₁NOS
• 分子量: 217.291
• InChiKey: KFSODTRTXWHIKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  63.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(nitromethyl)-4H-thieno[3,2-c]chromene 在 铁粉 、 氯化铵 作用下， 以 溶剂黄146 为溶剂， 以96%的产率得到(4H-thieno[3,2-c]chromen4-yl)methanamine
  参考文献：
  名称：

  [EN] MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS MULTICYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2011069063A3

文献信息

• Multicyclic compounds and methods of use thereof
  申请人：Shao Liming

  公开号：US08710245B2

  公开（公告）日：2014-04-29

  Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

  本文提供多环化合物、其合成方法、包含该化合物的药物组合物以及使用该化合物的方法。所提供的化合物对于治疗、预防和/或管理各种神经系统疾病，包括但不限于精神病和精神分裂症具有用途。
• MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Shao Liming

  公开号：US20130109677A1

  公开（公告）日：2013-05-02

  Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

  本文提供了多环化合物，其合成方法，包括该化合物的药物组合物，以及使用方法。本文提供的化合物对于治疗、预防和/或管理各种神经系统疾病非常有用，包括但不限于精神病和精神分裂症。
• Methods of treating schizophrenia
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US11129807B2

  公开（公告）日：2021-09-28

  Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.

  本文提供的方法用于确定化合物是否对治疗精神分裂症的特定症状域具有潜在疗效，例如治疗精神分裂症的阴性症状。此外，本文还提供了确定精神分裂症患者突出症状域的方法。此外，本文还提供了治疗与精神分裂症相关的阴性症状、认知功能障碍症状或两者的各种方法，包括向受试者施用治疗或预防有效量的各种化合物。
• US20140256712A1
  申请人：——

  公开号：——

  公开（公告）日：——
• METHODS OF TREATING SCHIZOPHRENIA
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20200129477A1

  公开（公告）日：2020-04-30

  Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.